Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy

被引:25
作者
van Rijssen, Thomas J. [1 ]
Singh, Sumit Randhir [2 ]
van Dijk, Elon H. C. [1 ]
Rasheed, Mohammed A. [2 ]
Vupparaboina, Kiran Kumar [2 ]
Boon, Camiel J. F. [1 ,3 ]
Chhablani, Jay [4 ]
机构
[1] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands
[2] LV Prasad Eye Inst, Dept Ophthalmol, Hyderabad, India
[3] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands
[4] Univ Pittsburgh, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15260 USA
关键词
Central serous chorioretinopathy; Choroidal vascularity index; Micropulse laser; Photodynamic therapy; PHOTOCOAGULATION; PATHOPHYSIOLOGY; EPLERENONE; THICKNESS; UPDATE; AREAS;
D O I
10.1007/s00417-020-04619-6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To assess whether treatment of chronic central serous chorioretinopathy (cCSC) with photodynamic therapy (PDT) and high-density subthreshold micropulse laser (HSML) results in choroidal vascularity index (CVI) changes that may account for the treatment effect. Methods Patients with cCSC were prospectively included and analyzed. Patients received either half-dose PDT or HSML treatment. CVI of the affected and unaffected eye was obtained before treatment, 6 to 8 weeks after treatment, and 7 to 8 months after treatment. Results At baseline, 29 eyes (29 patients) were included both in the PDT and in the HSML group. The mean (+/- standard deviation) CVI change in the HSML group between before PDT and 6 to 8 weeks after PDT was - 0.009 +/- 0.032 (p = 0.127), whereas this was 0.0025 +/- 0.037 (p = 0.723) between the visit before PDT and final visit. The patients in the PDT group had a CVI change of - 0.0025 +/- 0.037 (p = 0.723) between the visit before PDT and first visit after PDT, and a mean CVI change of - 0.013 +/- 0.038 (p = 0.080) between the visit before PDT and final visit. There was no significant correlation between CVI and BCVA at the measured time points, in both the HSML group (p = 0.885), and in the PDT group (p = 0.904). Moreover, no significant changes in CVI occurred in the unaffected eye at any time point. Conclusions PDT and HSML do not significantly affect CVI, and therefore a CVI change may not be primarily responsible for the treatment effect. The positive treatment effect of both interventions may rely on other mechanisms, such as an effect on choriocapillaris and/or retinal pigment epithelium function.
引用
收藏
页码:1191 / 1197
页数:7
相关论文
共 36 条
  • [1] Influence of scanning area on choroidal vascularity index measurement using optical coherence tomography
    Agrawal, Rupesh
    Wei, Xin
    Goud, Abhilash
    Vupparaboina, Kiran Kumar
    Jana, Soumya
    Chhablani, Jay
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95 (08) : e770 - e775
  • [2] CHOROIDAL VASCULARITY INDEX IN CENTRAL SEROUS CHORIORETINOPATHY
    Agrawal, Rupesh
    Chhablani, Jay
    Tan, Kara-Anne
    Shah, Shilpi
    Sarvaiya, Chintan
    Banker, Alay
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2016, 36 (09): : 1646 - 1651
  • [3] Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study
    Agrawal, Rupesh
    Gupta, Preeti
    Tan, Kara-Anne
    Cheung, Chui Ming Gemmy
    Wong, Tien-Yin
    Cheng, Ching-Yu
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [4] Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up
    Arsan, A.
    Kanar, H. S.
    Sonmez, A.
    [J]. EYE, 2018, 32 (04) : 726 - 733
  • [5] MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY A Pilot Study
    Bousquet, Elodie
    Beydoun, Talal
    Zhao, Min
    Hassan, Leila
    Offret, Olivier
    Behar-Cohen, Francine
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (10): : 2096 - 2102
  • [6] CENTRAL SEROUS CHORIORETINOPATHY IN ENDOGENOUS HYPERCORTISOLISM
    BOUZAS, EA
    SCOTT, MH
    MASTORAKOS, G
    CHROUSOS, GP
    KAISERKUPFER, MI
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (09) : 1229 - 1233
  • [7] Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial
    Breukink, Myrte B.
    Downes, Susan M.
    Querques, Giuseppe
    van Dijk, Elon H. C.
    den Hollander, Anneke I.
    Blanco-Garavito, Rocio
    Keunen, Jan E. E.
    Souied, Eric H.
    MacLaren, Robert E.
    Hoyng, Carel B.
    Fauser, Sascha
    Boon, Camiel J. F.
    [J]. TRIALS, 2015, 16
  • [8] The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy
    Breukink, Myrte B.
    den Hollander, Anneke I.
    Keunen, Jan E. E.
    Boon, Camiel J. F.
    Hoyng, Carel B.
    [J]. ACTA OPHTHALMOLOGICA, 2014, 92 (06) : E488 - E490
  • [9] Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy - One-year results of a randomized controlled trial
    Chan, Wai-Man
    Lai, Timothy Y. Y.
    Lai, Ricky Y. K.
    Liu, David T. L.
    Lam, Dennis S. C.
    [J]. OPHTHALMOLOGY, 2008, 115 (10) : 1756 - 1765
  • [10] Subthreshold Diode Micropulse Photocoagulation for the Treatment of Chronic Central Serous Chorioretinopathy with Juxtafoveal Leakage
    Chen, San-Ni
    Hwang, Jiunn-Feng
    Tseng, Li-Fang
    Lin, Chun-Ju
    [J]. OPHTHALMOLOGY, 2008, 115 (12) : 2229 - 2234